DR group 3 had significantly longer duration of diabetes (19.35 ± 4.60 years versus 13.22 ± 5.08 years; P < 0.001) and more often insulin than OHA therapy (87/13% versus 52/48%; P = 0.009) in comparison with DR group 1. This evidence concerns the gene INS and diabetes mellitus.